Huesgen Emily, Burgos Rodrigo, Goldstein Debra A, Max Blake, Jarrett Olamide D
Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, USA.
Antivir Ther. 2012;17(7):1385-8. doi: 10.3851/IMP2182. Epub 2012 Jun 22.
We describe a 55-year-old HIV-1-infected male who developed severe dyslipidaemia (total cholesterol 600 mg/dl, triglycerides >5,000 mg/dl, high density lipoprotein <5 mg/dl) after raltegravir was added to his lopinavir/ritonavir-containing regimen. To our knowledge, this is the first reported case of severe dyslipidaemia associated with the addition of raltegravir to a lopinavir/ritonavir-based regimen, suggestive of a possible drug interaction. The lipid profile quickly normalized following discontinuation of lopinavir/ritonavir and continuation of raltegravir, suggesting that lopinavir/ritonavir was the primary driver for the adverse event. With increasing interest in nucleoside-sparing regimens, knowledge of clinically significant adverse events such as this is important for HIV clinicians when selecting regimens for patients with highly resistant virus or drug tolerability issues.
我们描述了一名55岁的感染HIV-1的男性，在其含洛匹那韦/利托那韦的治疗方案中添加raltegravir后出现了严重的血脂异常（总胆固醇600mg/dl，甘油三酯>5000mg/dl，高密度脂蛋白<5mg/dl）。据我们所知，这是首例报告的在基于洛匹那韦/利托那韦的治疗方案中添加raltegravir后出现严重血脂异常的病例，提示可能存在药物相互作用。在停用洛匹那韦/利托那韦并继续使用raltegravir后，血脂水平迅速恢复正常，这表明洛匹那韦/利托那韦是该不良事件的主要驱动因素。随着对核苷类药物节省方案的兴趣增加，了解此类具有临床意义的不良事件对于HIV临床医生在为具有高度耐药病毒或药物耐受性问题的患者选择治疗方案时非常重要。
